Cargando…
Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology
Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF(165)). In this conte...
Autores principales: | Trujillo, Cleber A, Nery, Arthur A, Alves, Janaína M, Martins, Antonio H, Ulrich, Henning |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704523/ https://www.ncbi.nlm.nih.gov/pubmed/19668516 |
Ejemplares similares
-
Book Review: Anti-VEGF Use in Ophthalmology
por: Vora, Robin A.
Publicado: (2017) -
In vitro and in ovo experimental study of two anti-VEGF agents used in ophthalmology
por: Palfi, Mădălina-Casiana, et al.
Publicado: (2021) -
The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016) -
Screening and Improvement of an Anti-VEGF DNA Aptamer
por: Nonaka, Yoshihiko, et al.
Publicado: (2010) -
Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology
por: Cao, Jiamin, et al.
Publicado: (2023)